Japanese to make investment in development of Russian drugmaker R-Pharm

The Russian Direct Investment Fund (RDIF), one of Russia’s largest sovereign wealth funds, together with the Japan Bank for International Cooperation plans to make huge investments in the development of R-Pharm, one of Russia’s largest drugmakers, reports The Pharma Letter’s local correspondent.

That was recently confirmed by head of the Fund Kirill Dmitriev. The planned value of investments is not disclosed, however, according to some sources close to the Fund, it may be in the range of $50-$70 million, with the possibility of a further increase in the coming years.

The majority of the funds are expected to be invested in setting up production of new drugs at the facilities of R-Pharm. As part of these plans, the company may produce its own drugs, as well as drugs of some global drugmakers that will take place on the basis of contract manufacturing.